<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167206</url>
  </required_header>
  <id_info>
    <org_study_id>0312M54991</org_study_id>
    <secondary_id>MT2003-18</secondary_id>
    <nct_id>NCT00167206</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation for Fanconi Anemia</brief_title>
  <official_title>A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether thymic shielding during total body
      irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia
      patients undergoing alternate donor (not a matched sibling) stem cell transplants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be given the same treatment regimen of total body irradiation (TBI),
      Fludarabine, Cyclophosphamide, and anti-thymocyte globulin (ATG), followed by an alternate
      donor stem cell transplant. Since this treatment regimen has been given before, without
      thymic shielding, we will compare the outcomes of these patients with the historical data
      from subjects who did not receive thymic shielding.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Treatment with thymic shielding found safe, another study started.
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment</measure>
    <time_frame>Day 42 after hematopoietic cell transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to Day 42 post-transplant. Hematopoietic recovery and engraftment is defined as the first of three consecutive days the patient's absolute neutrophil count is greater than or equal to 0.5X10^9/Liter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Exhibited Secondary Graft Failure</measure>
    <time_frame>Day 100 after hematopoietic cell transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. A complication after Bone Marrow Transplant in which the transplanted stem cells do not grow in the recipient's bone marrow and thus do not produce new blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Graft Versus-Host Disease (aGVHD)</measure>
    <time_frame>Day 100 after hematopoietic cell transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as &quot;foreign&quot; and mount an immunologic attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chronic Graft Versus-Host Disease (GVHD)</measure>
    <time_frame>1 year after hematopoietic cell transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as &quot;foreign&quot; and mount an immunologic attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Exhibited Regimen-related Toxicity (RRT)</measure>
    <time_frame>1 year after hematopoietic cell transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. Regimen-related toxicity involves harmful effects in an organism through exposure to the treatment given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution - Mean Value (1 Year)</measure>
    <time_frame>1 year post-transplant.</time_frame>
    <description>Calculated mean value of patient CD4 values collected at intervals from Day 30 through 1 year post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution - Mean Value (2 Years)</measure>
    <time_frame>at 2 years after transplant</time_frame>
    <description>Calculated mean value of patient CD4 values collected at intervals from Day 30 through 2 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive at 1 Year</measure>
    <time_frame>1 year after transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive at 2 Years</measure>
    <time_frame>2 years after transplant</time_frame>
    <description>Calculated from Day 1 of hematopoietic cell transplant to 2 years post-transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>HSCT Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplant</intervention_name>
    <description>Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.</description>
    <arm_group_label>HSCT Patients</arm_group_label>
    <other_name>Bone Marrow Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thymic Shielding During Radiation</intervention_name>
    <description>protecting the thymus during total body radiation (450 cGy administered)</description>
    <arm_group_label>HSCT Patients</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.</description>
    <arm_group_label>HSCT Patients</arm_group_label>
    <other_name>Radiation Therapy, Therapuetic Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Fludarabine</intervention_name>
    <description>Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line</description>
    <arm_group_label>HSCT Patients</arm_group_label>
    <other_name>Cytoxan, Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be less than (&lt;) 18 years of age with a diagnosis of Fanconi anemia.

          -  Patients must have an HLA-A, B, DRB1 identical unrelated donor or less than or equal
             to (â‰¤)1 antigen mismatched related (non-HLA-matched sibling) or &lt;1 antigen mismatched
             unrelated UCB donor. Patients and donors will be typed for HLA-A and B using
             serological or molecular techniques and for DRB1 using high resolution molecular
             typing.

          -  Patients with FA must have aplastic anemia (AA), myelodysplastic syndrome without
             excess blasts, or high risk genotype as defined below.

               -  Aplastic anemia is defined as having at least one of the following when not
                  receiving growth factors or transfusions

               -  Platelet count &lt;20 x 10^9/L

               -  ANC &lt;5 x 10^8/L

               -  Hgb &lt;8 g/dL

               -  Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal
                  anomalies

               -  High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2
                  mutations)

          -  Adequate major organ function including

               -  Cardiac: ejection fraction greater than (&gt;)45%

               -  Hepatic: bilirubin, AST/ALT, ALP &lt;2 x normal

               -  Karnofsky performance status &gt;70% or Lansky performance status &gt;50%

          -  Women of child-bearing age must be using adequate birth control and have a negative
             pregnancy test

        Exclusion Criteria:

          -  Available HLA-genotypically identical related donor

          -  History of gram negative sepsis or systemic fungal infection (proven or suspected
             based on radiographic studies)

          -  Refractory anemia with excess blasts, or leukemia

          -  Active central nervous system (CNS) leukemia at time of hematopoietic cell transplant
             (HCT)

          -  History of squamous cell carcinoma of the head/neck/cervix within 2 years of HCT

          -  Pregnant or lactating female

          -  Prior radiation therapy preventing use of total body irradiation (TBI) 450 centigray
             (cGy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret MacMillan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>July 7, 2009</results_first_submitted>
  <results_first_submitted_qc>October 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2009</results_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Thymic Shielding</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intent-To-Treat</title>
          <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intent-To-Treat</title>
          <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to Day 42 post-transplant. Hematopoietic recovery and engraftment is defined as the first of three consecutive days the patient's absolute neutrophil count is greater than or equal to 0.5X10^9/Liter.</description>
        <time_frame>Day 42 after hematopoietic cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to Day 42 post-transplant. Hematopoietic recovery and engraftment is defined as the first of three consecutive days the patient's absolute neutrophil count is greater than or equal to 0.5X10^9/Liter.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Exhibited Secondary Graft Failure</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. A complication after Bone Marrow Transplant in which the transplanted stem cells do not grow in the recipientâ€™s bone marrow and thus do not produce new blood cells.</description>
        <time_frame>Day 100 after hematopoietic cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Exhibited Secondary Graft Failure</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. A complication after Bone Marrow Transplant in which the transplanted stem cells do not grow in the recipientâ€™s bone marrow and thus do not produce new blood cells.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Graft Versus-Host Disease (aGVHD)</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as &quot;foreign&quot; and mount an immunologic attack.</description>
        <time_frame>Day 100 after hematopoietic cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Graft Versus-Host Disease (aGVHD)</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as &quot;foreign&quot; and mount an immunologic attack.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chronic Graft Versus-Host Disease (GVHD)</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as &quot;foreign&quot; and mount an immunologic attack.</description>
        <time_frame>1 year after hematopoietic cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chronic Graft Versus-Host Disease (GVHD)</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as &quot;foreign&quot; and mount an immunologic attack.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Exhibited Regimen-related Toxicity (RRT)</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. Regimen-related toxicity involves harmful effects in an organism through exposure to the treatment given.</description>
        <time_frame>1 year after hematopoietic cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Exhibited Regimen-related Toxicity (RRT)</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. Regimen-related toxicity involves harmful effects in an organism through exposure to the treatment given.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution - Mean Value (1 Year)</title>
        <description>Calculated mean value of patient CD4 values collected at intervals from Day 30 through 1 year post-transplant.</description>
        <time_frame>1 year post-transplant.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution - Mean Value (1 Year)</title>
          <description>Calculated mean value of patient CD4 values collected at intervals from Day 30 through 1 year post-transplant.</description>
          <units>Number of CD4 cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="860" spread="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution - Mean Value (2 Years)</title>
        <description>Calculated mean value of patient CD4 values collected at intervals from Day 30 through 2 years post-transplant.</description>
        <time_frame>at 2 years after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution - Mean Value (2 Years)</title>
          <description>Calculated mean value of patient CD4 values collected at intervals from Day 30 through 2 years post-transplant.</description>
          <units>Number of CD4 cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100" spread="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive at 1 Year</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year post-transplant.</description>
        <time_frame>1 year after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at 1 Year</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to 1 year post-transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive at 2 Years</title>
        <description>Calculated from Day 1 of hematopoietic cell transplant to 2 years post-transplant.</description>
        <time_frame>2 years after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at 2 Years</title>
          <description>Calculated from Day 1 of hematopoietic cell transplant to 2 years post-transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Start of study through 1 year after transplant.</time_frame>
      <desc>Adverse events were not collected for this study population as it is not routinely done. Graft versus Host Disease and treatment related toxicity is reported in the secondary outcome measure section.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intent-To-Treat</title>
          <description>All patients with Fanconi anemia who received thymic shielding during total body irradiation (450 cGy).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study ended early as thymic shielding was found to be safe. Therefore, a new study was designed using thymic shielding.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret MacMillan, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2778</phone>
      <email>macmi002@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

